AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Royalty Pharma plc Class A Ordinary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00V1L5ZR1
63.86▲ 0.11 (0.17%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
63.75
Day's Range
63.01 – 63.97
52-Week Range
35.92 – 64.38
Volume
3.8M
Avg Volume
3.0M
Share Statistics
Shares Outstanding
Employees
100
Exchange
XNAS
Listed
2020-06-16
Share count as of July 31, 2026

Royalty Pharma plc Class A Ordinary Shares (RPRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Royalty Pharma plc Class A Ordinary Shares (RPRX)
What is Royalty Pharma plc Class A Ordinary Shares's Market Cap?
Royalty Pharma plc Class A Ordinary Shares's Market Cap is $36.7B, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Enterprise Value?
Royalty Pharma plc Class A Ordinary Shares's Enterprise Value is $44.9B, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Trailing P/E?
Royalty Pharma plc Class A Ordinary Shares's Trailing P/E is 45.2×, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Price / Sales?
Royalty Pharma plc Class A Ordinary Shares's Price / Sales is 14.5×, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's EV / Revenue?
Royalty Pharma plc Class A Ordinary Shares's EV / Revenue is 17.7×, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's EV / EBITDA?
Royalty Pharma plc Class A Ordinary Shares's EV / EBITDA is 29.6×, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Revenue (TTM)?
Royalty Pharma plc Class A Ordinary Shares's Revenue (TTM) is $2.5B, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Net Income (TTM)?
Royalty Pharma plc Class A Ordinary Shares's Net Income (TTM) is $812.0M, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's EBITDA?
Royalty Pharma plc Class A Ordinary Shares's EBITDA is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is Royalty Pharma plc Class A Ordinary Shares's Diluted EPS (TTM)?
Royalty Pharma plc Class A Ordinary Shares's Diluted EPS (TTM) is 1.41, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RPRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total income and other revenues
YoY growth+16.5%+11.0%+4.8%+7.9%
Operating expense/(income)
Provision for changes in expected cash flows from financial royalty assets
Provision for credit losses on unfunded commitments
Research and development funding expense
General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4)
Financial royalty asset impairment——
Total operating expense, net
% of revenue80.3%10.7%37.6%29.9%
Operating income
% of revenue19.7%89.3%62.4%70.1%
Other (income)/expense
Equity in earnings of equity method investees
Interest expense
(Gains)/losses on equity securities
Losses on available for sale debt securities
Interest income
Other non-operating expenses, net
Total other expense, net
Consolidated net income before tax
Consolidated net income
% of revenue12.1%74.3%57.2%72.9%
Net income attributable to non-controlling interests
Net income attributable to Royalty Pharma plc
% of revenue2.7%46.7%34.4%47.3%
Basic (in dollars per share)
Diluted (in dollars per share)